SoftOx Solutions Advances Cystic Fibrosis Treatment with Phase 2a Trial Application and Stability Breakthrough
核心洞察
SoftOx Solutions (搜索) has submitted a clinical trial application to the Danish Medicines Agency for a dose-escalation Phase 2a study in cystic fibrosis patients, marking a significant milestone toward commercialization.
The company published breakthrough data demonstrating that hypochlorous acid can be stored as a stable solid precursor for ≥24 months with ≤5% degradation and near-instant conversion upon activation.
The planned Phase 2a trial will evaluate safety at higher doses and bacterial load reduction in cystic fibrosis patients, targeting a market potential exceeding USD 600 million in the US and Europe.
SoftOx Solutions (搜索) AS has formally submitted a clinical trial application (CTA) to the Danish Medicines Agency for approval of its upcoming dose-escalation Phase 2a clinical study in people with cystic fibrosis (CF). The submission represents a decisive step toward initiating human efficacy testing of SoftOx's inhalation solution (SIS) and culminates extensive preclinical work and strategic refinement of the company's clinical focus.
The planned Phase 2a trial will evaluate safety at higher doses and provide important data on bacterial load reduction in people with CF, where unmet medical need remains high. The study is expected to start in Q1 2026, subject to regulatory approval.
Market Opportunity and Commercial Potential
The CTA filing positions SoftOx on a path toward commercialization in cystic fibrosis, targeting approximately 13,000 addressable patients in the US and Europe with a market potential of more than USD 600 million. The development also paves the way for expansion into related indications such as non-CF bronchiectasis, targeting approximately 445,000 addressable patients in the same regions with a market exceeding USD 5 billion.
Stability Breakthrough Reinforces Clinical Strategy
Supporting its clinical advancement, SoftOx announced published breakthrough data on the stability of hypochlorous acid (HOCl), the core component of its inhaled therapy. The preformulation study, published in the Journal of Drug Delivery Science and Technology (Pham et al., 2025), demonstrates that storing HOCl as a solid precursor and generating it only when needed overcomes the long-standing stability barrier that has limited higher-strength HOCl formulations.
The research showed that the powder was highly stable for ≥24 months at approximately 23°C when stored dry (≤5% degradation) and demonstrated near-instant conversion on activation (≥99% within seconds).
Leadership Perspective
CEO Thomas Bjarnsholt emphasized the significance of these developments: "This submission underlines our commitment to advancing SoftOx's pipeline and delivering on our strategic goals. It is a key inflection point for the company, demonstrating progress toward addressing significant unmet medical needs."
Regarding the stability findings, Bjarnsholt added: "These findings validate the foundation of our inhaled SIS program. Combined with our focused clinical path in cystic fibrosis, they mark a pivotal moment for SoftOx."
Technology Platform and Future Prospects
SoftOx Solutions (搜索) is developing highly effective pan-antimicrobial pharmaceuticals targeting bacteria, viruses, and fungi. The technology is based on extensive research and development in partnership with leading Nordic research institutes. Positive progress and data from the upcoming study will further enhance SoftOx's attractiveness as a potential partner for global pharmaceutical companies.
The upcoming proof-of-concept trial will evaluate safety at higher doses in healthy volunteers and demonstrate bacterial load reduction in people with cystic fibrosis. Positive results would open the way to broader indications, including non-CF bronchiectasis.